Table 3.
Adherence to OACs (PDC ≥80%), Stratified by Index Medication (N=64 661)
| Apixaban (n=3900) | Dabigatran (n=10 235) | Rivaroxaban (n=12 336) | All NOACs (n=26 471) | Warfarin (n=38 190) | P Value (All NOACs Pooled vs Warfarin) | |
|---|---|---|---|---|---|---|
| Unadjusted adherencea | ||||||
| All | 61.9% | 38.5% | 50.5% | 47.5% | 40.2% | <0.001 |
| CHA2DS2‐VASc score 0 or 1 | 50.1% | 24.6% | 36.5% | 32.6% | 27.1% | <0.001 |
| CHA2DS2‐VASc score 2 or 3 | 62.0% | 40.3% | 52.8% | 49.1% | 38.1% | <0.001 |
| CHA2DS2‐VASc score ≥4 | 64.0% | 42.4% | 53.2% | 51.1% | 42.3% | <0.001 |
| Adjusted adherence, 95% CIb | ||||||
| All | 52.1% (50.3–53.9) | 45.9% (44.8–47.1) | 47.6% (46.6–48.7) | 47.5% (46.7–48.2) | 38.7% (38.1–39.3) | <0.001 |
| CHA2DS2‐VASc score 0 or 1 | 40.6% (35.8–45.4) | 28.6% (26.3–30.9) | 30.8% (28.7–32.9) | 30.8% (29.3–32.3) | 25.2% (23.4–27.0) | <0.001 |
| CHA2DS2‐VASc score 2 or 3 | 51.9% (48.9–55.0) | 46.9% (45.1–48.6) | 48.8% (47.2–50.5) | 48.3% (47.2–49.5) | 37.3% (36.3–38.4) | <0.001 |
| CHA2DS2‐VASc score ≥4 | 54.1% (51.8–56.5) | 48.7% (47.1–50.3) | 50.1% (48.7–51.5) | 50.1% (49.0–51.1) | 42.0% (41.3–42.7) | <0.001 |
OAC, oral anticoagulant; PDC, proportion of days covered; NOAC, non–vitamin K antagonist oral anticoagulant; CHA 2 DS 2‐VASc, risk based on the presence of congestive heart failure, hypertension, age ≥75 y, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, sex category.
a
Unadjusted adherence was the percentage of patients with PDC ≥80%.
b
Adjusted adherence was the predicted probability of PDC ≥80% based on multivariable logistic regression.